Dennis van den Berg

Mr. Dennis van den Berg

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2024 in European Journal of Physiotherapy
Verified
Journal Article
Open access
DBDennis van den Berg
Dennis van den Berg
HKHenri Kiers
Henri Kiers
EMEsther T. Maas
Esther T. Maas
TVThea P. M. Vliet Vlieland
Thea P. M. Vliet Vlieland
RORaymond W. J. G. Ostelo
Raymond W. J. G. Ostelo
To explore the frequency of administration and the usage of the Hip Disability and Knee injury Osteoarthritis Outcome Scores (HOOS/KOOS) and their Physical function Short forms (HOOS-PS/KOOS-PS) by physiotherapists after total hip and knee arthroplasties (THA/TKA). A cross-sectional study using an open online survey. Primary care physiotherapy practices affiliated with the Dutch Association for Quality in Physiotherapy. Physiotherapists with experience treating over five patients with a THA or TKA within the past 5 years. One hundred and sixty-six physiotherapists completed the survey (median age: 40.0 years, female: 34%, median experience: 15.0 years). Of those, 32 did not administer the HOOS(-PS) or KOOS(-PS) (‘non-users’), 41 administered only due to organisational requirements or guideline recommendations (‘passive users’) and 93 actively used them for individual patient treatment purposes (‘active users’). ‘Treatment evaluation’, ‘diagnosis’, and ‘prognosis’ were most often reported as potential reasons to actively use the HOOS(-PS) or KOOS(-PS) for individual treatment purposes. Determinants associated with active use of the HOOS(-PS) or KOOS(-PS) appeared to be fewer years of experience as a physiotherapist, a larger treatment volume of THA/TKA, a younger age, and higher attitude scores regarding PROM use. Most responding physiotherapists administer the HOOS(-PS) or KOOS(-PS), but their use for individual treatment is limited. Active users appear to be less experienced, younger, treat larger volumes of THA/TKA, and possess a more positive attitude towards using patient-reported outcome measures.

15 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TSThomas Swartjes
Thomas Swartjes
PSPeng Shang
Peng Shang
DBDennis van den Berg
Dennis van den Berg
TKTim A. Künne
Tim A. Künne
NGNiels Geijsen
Niels Geijsen
RNRichard A. Notebaart
Richard A. Notebaart
CRISPR-Cas has revolutionized genome editing and has a great potential for applications, such as correcting human genetic disorders. To increase the safety of genome editing applications, CRISPR-Cas may benefit from strict control over Cas enzyme activity. Previously, anti-CRISPR proteins and designed oligonucleotides have been proposed to modulate CRISPR-Cas activity. Here we report on the potential of guide-complementary DNA oligonucleotides as controlled inhibitors of Cas9 ribonucleoprotein complexes. First, we show that DNA oligonucleotides down-regulate Cas9 activity in human cells, reducing both on and off-target cleavage. We then used in vitro assays to better understand how inhibition is achieved and under which conditions. Two factors were found to be important for robust inhibition: the length of the complementary region, and the presence of a PAM-loop on the inhibitor. We conclude that DNA oligonucleotides can be used to effectively inhibit Cas9 activity both ex vivo and in vitro .

23 September 2026 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
DBDennis van den Berg
Dennis van den Berg
EMEsther T. Maas
Esther T. Maas
TVThea Vlieland
Thea Vlieland
MRMax Reijman
Max Reijman
HKHenri Kiers
Henri Kiers
WZWierd P. Zijlstra
Wierd P. Zijlstra

4 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DBDennis van den Berg
Dennis van den Berg
EMEsther T. Maas
Esther T. Maas
RERosa-Lynn Edelaar
Rosa-Lynn Edelaar
MAMathijs B. Arendsen
Mathijs B. Arendsen
ELElizabeth J. de Louw
Elizabeth J. de Louw
MDMarianne H. Donker
Marianne H. Donker
Background: Clinical guidelines for physiotherapy following total hip and knee arthroplasty (THA/TKA) recommend using Patient-Reported Outcome Measures (PROMs) like the Hip disability and Knee injury Osteoarthritis Outcome Score (HOOS/KOOS). However, it remains unclear how physiotherapists use these PROMs in daily clinical practice. Objective: To explore primary care physiotherapists’ experiences with the HOOS/KOOS in daily clinical practice following THA and TKA. Methods: Thirteen physiotherapists in the Netherlands were recruited via convenience sampling. Data were collected through semi-structured interviews, which explored HOOS/KOOS use in clinical practice, administrative regulations, and applications beyond patient care, as well as think-aloud interviews to capture perceptions of the content of these PROMs and interpretations of hypothetical patient scores. Interviews were analysed using reflexive thematic analysis. Results: The physiotherapists’ ages ranged from 25 to 54y, with annual THA/TKA volumes from 5 to 50 patients. Three themes emerged, as follows: (1) “Physiotherapists use the HOOS/KOOS for various purposes in daily clinical practice”, including complementing history taking and monitoring patient progress; (2) “Perceptions of the relevance of the HOOS/KOOS for daily clinical practice vary per item, domain, and version,” with items related to daily life activities and psychosocial factors being perceived as more valuable; and (3) “Practical aspects of HOOS/KOOS administration influence their use in daily clinical practice,” with electronic health records (EHRs) that facilitate PROM administration enhancing their use, while administrative regulations limit this. Conclusions: Physiotherapists experience HOOS/KOOS items related to daily life activities and psychosocial factors useful for history-taking and monitoring patient progress, particularly when embedded in EHRs that facilitate PROM administration.